Colistin-induced nephrotoxicity and risk factors in intensive care unit: estimating from the routine laboratory findings Colistin-Induced Nephrotoxicity and Risk Factors

Main Article Content

Ahmet Ziya Şahin
Betül Kocamer Şimşek

Abstract

Objective: In this study we aimed to evaluate the patients treated with colistin in an intensive care unit (ICU) and risk factors emergence of acute renal failure (ARF) after colistine treatment.


Materials and Methods: Patients treated with colistine in the ICU between June 2016 and September 2018 were reviewed in this retrospective study. The 37 patients who were received colistine more than 3 days due to detection of Acinetobacter baumannii in culture of tracheal aspirate specimen were included in this study. Sociodemographic and clinical data and also biochemical parameters, glomerular filtration rates (GFR), APACHE-II, RIFLE and AKIN scores were examined. Patients were divided into two groups as ARF-developing and non-ARF-developing. Follow - up parameters were compared between these two groups.


Results: The patient group consisted of 26 males and 11 females. The mean age of the patients was 61.0 ± 19.33 years and %45 of the patients developed ARF. Mean APACHE-II score was 20.7±5.6. Mean age was significantly older in ARF patients. Onset day of colistine was significantly lower in patients with ARF. Significant relationships were found with the creatinine, albumin, AST, ALT and BUN parameters between ARF.


Conclusion: Older age and early initiation of colistin treatment in the ICU should be considered to be risky for ARF development. Before colistin treatment BUN, creatinine, CRP, albumin and AST levels should be considered to be risky for ARF development. After colistin treatment ALT, BUN, creatinine, urine output, platelet, AST, arterial blood gas base excess levels, urine pH, and protein amount in urine should be followed carefully.

Downloads

Download data is not yet available.

Article Details

How to Cite
Şahin, A. Z., & Kocamer Şimşek, B. (2019). Colistin-induced nephrotoxicity and risk factors in intensive care unit: estimating from the routine laboratory findings . Medical Science and Discovery, 6(9), 210-220. https://doi.org/10.36472/msd.v6i9.301
Section
Research Article

References

Terpos, E. (2016). International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. Journal of Clinical Oncology, 34, 1544–1557. https://doi.org/10.1200/jco.2015.65.0044
2. Brigle K1, Pierre A2, Finley-Oliver E3, Faiman B4, Tariman JD5, Miceli T6. Myelosuppression, Bone Disease, and Acute Renal Failure: Evidence-Based Recommendations for Oncologic Emergencies. Clin J Oncol Nurs. 2017 Oct 1;21(5 Suppl):60-76. doi: 10.1188/17.CJON.S5.60-76.
3. Iavecchia L1, Cereza García G1, Sabaté Gallego M1, Vidal Guitart X1, Ramos Terrades N2, de la Torre J2, Segarra Medrano A2, Agustí Escasany A3. Drug-related acute renal failure in hospitalised patients.Nefrologia. 2015 Nov-Dec;35(6):523-32. doi: 10.1016/j.nefro.2015.09.007. Epub 2015 Oct 21.
4. K. Nash, A. Hafeez, S. Hou. Hospital-acquired renal insufficiency. Am J Kidney Dis, 39 (2002), pp. 930-936 http://dx.doi.org/10.1053/ajkd.2002.32766
5. Koch-Weser J, Sidel VW, Federman EB, et al: Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970;72:857-868
6. Poirel L, Jayol A, Nordmanna P: Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin Microbiol Rev 2017;30:557-596.
7. Menna P1, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M.
Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy. Chemotherapy. 2018;63(1):35-38. doi: 10.1159/000484974. Epub 2017 Dec 22.
8. . Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589–601. doi: 10.1016/S1473-3099(06)70580-1.
9. Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2:1–138.
10. Makris, K., & Spanou, L. (2016). Acute kidney injury: definition, pathophysiology and clinical phenotypes. The Clinical Biochemist Reviews, 37(2), 85.
11. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care. 2011;1:14.

12. Gaynes R, Edwards JR, National Nosocomial Infections Surveillance System Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005;41:848–54.
13. Knaus, William A., et al. "The APACHE III prognostic system: risk prediction of hospital mortality for critically III hospitalized adults." Chest 100.6 (1991): 1619-1636.
14. Koksal, I., Kaya, S., Gencalioglu, E., & Yilmaz, G. (2016). Evaluation of risk factors for intravenous colistin use-related nephrotoxicity. Oman medical journal, 31(4), 318.
15. Mapel, D. (2014). Renal and hepatobiliary dysfunction in chronic obstructive pulmonary disease. Current opinion in pulmonary medicine, 20(2), 186-193.
16. Kirtane AJ, Leder DM, Waikar SS, Chertow GM, Ray KK, Pinto DS, Karmpaliotis D, Burger AJ, Murphy SA, Cannon CP, Braunwald E, Gibson CM, TIMI Study Group. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol. 2005 Jun 7; 45(11):1781-6
17. Rached E. Hoffmann D. Blumbach K. Weber K. Dekant W. Mally A. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin A in vivo and in vitro. Toxicol. Sci. (2008);103:371–381
18. Kim, S. Y., & Moon, A. (2012). Drug-induced nephrotoxicity and its biomarkers. Biomolecules & therapeutics, 20(3), 268.
19. Vaidya V. S. Ferguson M. A. Bonventre J. V. Biomarkers of acute kidney injury. Annu. Rev. Pharmacol. Toxicol. (2008);48:463–493
20. Mogensen C. E. Urinary albumin excretion in early and long-term juvenile diabetes. Scand. J. Clin. Lab. Invest. (1971);28:101–109
21. Park, S. Y., Choo, J. W., Kwon, S. H., Yu, S. N., Lee, E. J., Kim, T. H., ... & Jeon, M. H. (2013). Risk factors for mortality in patients with Acinetobacter baumannii bacteremia. Infection & chemotherapy, 45(3), 325-330.
22. Javan, A. O., Shokouhi, S., & Sahraei, Z. (2015). A review on colistin nephrotoxicity. European journal of clinical pharmacology, 71(7), 801-810
23. Gai Z, Samodelov SL, Kullak-Ublick GA, Visentin M. Molecular Mechanisms of Colistin-Induced Nephrotoxicity. Molecules. 2019 Feb 12;24(3). pii: E653. doi: 10.3390/molecules24030653.
24. Dai, C.; Li, J.; Tang, S.; Li, J.; Xiao, X. Colistin-induced nephrotoxicity in mice involves the mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob. Agents Chemother. 2014, 58, 4075–4085
25. Ozyilmaz E, Ebinc FA, Derici U, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med. 2011;37:141–146.